Skip to main content
EJNMMI Reports
Fig. 2 | European Journal of Hybrid Imaging

Fig. 2

From: Associations of quantitative whole-body PSMA-PET metrics with PSA progression status under long-term androgen deprivation therapy in prostate cancer patients: a retrospective single-center study

Fig. 2

a PSA and PSMA-PET metrics concordance: 75-year-old male with Gleason Score 3 + 4 = 7 castration-sensitive PCa treated with Lupron between PET1 and PET2. Patient had WB-PSMA-VOL ≥ 20%, WB-PSMA-SUVmean ≥ 30%, was classified as RECIP-PD, had new lesions on PET2, and experienced PSA progression at the time of PET2. b PSA and PSMA-PET metrics concordance: 66-year-old male with Gleason Score 3 + 4 = 7 castration-sensitive PCa treated with Lupron and Casodex between PET1 and PET2. Patient had WB-PSMA-VOL < 20%, WB-PSMA-SUVmean < 30%, was classified as RECIP-non-PD, had no new lesions on PET2, and did not experience PSA progression at the time of PET2. c PSA and PSMA-PET metrics discordance: 70-year-old male with Gleason Score 5 + 5 = 10 castration-sensitive PCa treated with Lupron and Casodex between PET1 and PET2. Patient had WB-PSMA-VOL < 20%, WB-PSMA-SUVmean < 30%, was classified as RECIP-non-PD, had new lesions on PET2, but did experience PSA progression at the time of PET2

Back to article page